Dogs Of The Dow Continue Outperforming Broader Market

The Dogs of the Dow strategy has outperformed through November 2025, delivering a year-to-date total return of 20.96% versus the Dow Jones Industrial Average's 13.86% and the S&P 500's 17.74%. Two of the top three performers among the ten high-yield DJIA selections are healthcare names Johnson & Johnson and Amgen, underscoring a broadening market participation beyond traditional cyclical sectors. The piece reiterates the strategy’s rules—selecting the ten highest dividend-yielding DJIA stocks at year-end—and highlights HORAN Wealth's dividend-focused, steady-return investment approach.

Analysis

Market structure: The Dogs of the Dow YTD outperformance (20.96% vs DJIA 13.86% and S&P 17.74%) signals a near-term investor bias back toward high-yield, cash-flow-stable large caps—direct beneficiaries include JNJ and AMGN and dividend-focused ETFs; higher demand for these names can compress yields 50–150bp relative to peers over 3–6 months. Losers are likely growth/low-yield tech names and cyclicals that lose relative flows; index-driven year-end reconstitution could amplify buying in late Dec and create short-term crowding. Cross-asset impact is modest but real: equity demand for yield should exert slight downward pressure on intermediate Treasury yields (~5–15bp) and depress equity volatility in health care options while leaving FX and commodity moves signal-dependent.

Risk assessment: Tail risks include regulatory actions (FDA/adverse rulings), trial failures for AMGN, and legal/regulatory shocks for JNJ; quantify a tail: a major adverse FDA decision or regulatory fine could produce a 20–35% drawdown in months. Immediate (days) risk is momentum reversal; short-term (weeks/months) risk is dividend yield compression and rebalancing; long-term (quarters/years) risk is dividend sustainability if FCF/Dividend ratio falls below ~1.2. Catalysts to accelerate reversal: Fed rate surprise, large insider selling, or negative Phase III readouts.

Trade implications: Tactical: establish modest 2–3% long positions in JNJ and AMGN with 12-month return targets of +12–18% and hard stop-loss at -8% (or on dividend cut). Use 60–90 day cash-secured puts 5–7% OTM on JNJ/AMGN to enhance yield if willing to own; sell covered calls 3–6 months OTM after entry to harvest income. Consider a relative-value pair long JNJ vs short CAT (1:1 notional) for 3–6 months to express defensive/quality bias while hedging macro cyclicality.

Contrarian angles: Consensus overlooks crowding risk and duration-like behavior of high dividend names—if rates re-price higher by 50–75bp, expect 8–12% downside; Dogs outperformance historically concentrated in recovery legs (post-2009) but reversed when growth reaccelerates. Mispricing exists in option markets: implied vols on JNJ/AMGN sit ~20–30% lower than peers—sell premium selectively; avoid allowing dividend-chasing to exceed 10–15% portfolio weight without trigger-based trimming (15–20% price gain or FCF coverage <1.2).

Key Decisions for Investors

• Establish 2–3% long positions in JNJ and AMGN each with a 12-month target total return of +12–18%; implement hard stop-loss at -8% absolute or immediately if company issues dividend cut guidance.
• Sell 60–90 day cash-secured puts 5–7% OTM on JNJ and AMGN to collect premium and set effective buy-in levels; roll only if premium <1.5% of strike or implied vol drops >30% from entry.
• Implement a 1:1 pair trade: long JNJ vs short CAT (Caterpillar) for 3–6 months to capture defensive overweight; trim if JNJ outperforms CAT by >15% or if industrial activity prints accelerate >2% QoQ.
• Cap total dividend/high-yield equity exposure to 10–15% of the equity sleeve; upon any single-name run-up of 15–20% or if FCF/Dividend coverage falls below 1.2x, trim position size by 25% to control crowding and dividend sustainability risk.